Literature DB >> 26726940

Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.

A Hanif1, P N Hari2, E Atallah3, K-S B Carlson3, M C Pasquini3, L C Michaelis3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26726940     DOI： 10.1038/bmt.2015.295

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

1.  Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Authors:  Haefaa Alchalby; Anita Badbaran; Tatjana Zabelina; Guido Kobbe; Joachim Hahn; Daniel Wolff; Martin Bornhäuser; Christian Thiede; Herrad Baurmann; Wolfgang Bethge; York Hildebrandt; Ulrike Bacher; Boris Fehse; Axel R Zander; Nicolaus Kröger
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

2.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Authors:  T Stübig; H Alchalby; M Ditschkowski; D Wolf; G Wulf; T Zabelina; C Wolschke; F Ayuk; N Kröger
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 5.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors:  Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal:  Blood       Date:  2012-06-14       Impact factor: 22.113

Review 6.  Myelofibrosis with myeloid metaplasia.

Authors:  A Tefferi
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

7.  Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.

Authors:  Damiano Rondelli; Giovanni Barosi; Andrea Bacigalupo; Josef T Prchal; Uday Popat; Emilio P Alessandrino; Jerry L Spivak; B Douglas Smith; Hans G Klingemann; Steven Fruchtman; Ronald Hoffman
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

8.  Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.

Authors:  A Bacigalupo; M Soraru; A Dominietto; S Pozzi; S Geroldi; M T Van Lint; A Ibatici; A M Raiola; F Frassoni; F De Stefano; S Verdiani; L Casarino; G Barosi
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

9.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Nicolaus Kröger; Ernst Holler; Guido Kobbe; Martin Bornhäuser; Rainer Schwerdtfeger; Herrad Baurmann; Arnon Nagler; Wolfgang Bethge; Matthias Stelljes; Lutz Uharek; Hannes Wandt; Andreas Burchert; Paolo Corradini; Jörg Schubert; Martin Kaufmann; Peter Dreger; Gerald G Wulf; Hermann Einsele; Tatjana Zabelina; Hans Michael Kvasnicka; Jürgen Thiele; Ronald Brand; Axel R Zander; Dietger Niederwieser; Theo M de Witte
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

10.  Epidemiology of myeloproliferative neoplasms in the United States.

Authors:  Jyotsna Mehta; Hongwei Wang; Sheikh Usman Iqbal; Ruben Mesa
Journal:  Leuk Lymphoma       Date:  2013-07-29
View more
  3 in total

1.  Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms.

Authors:  Sara Beltrán Ponce; Saurabh Chhabra; Parameswaran Hari; Selim Firat
Journal:  Adv Radiat Oncol       Date:  2022-04-10

Review 2.  Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.

Authors:  Lining Zhang; Fan Yang; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-02-13

Review 3.  The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.

Authors:  Sung-Yong Kim; Sung Hwa Bae; Soo-Mee Bang; Ki-Seong Eom; Junshik Hong; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Min Kyoung Kim; Soo-Jeong Kim; Yeung-Chul Mun; Seung-Hyun Nam; Jinny Park; Jong-Ho Won; Chul Won Choi
Journal:  Korean J Intern Med       Date:  2020-12-04       Impact factor: 2.884
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.